Nurix Therapeutics, Inc. Common stock (NRIX) Stock Price

NRIXStock

$24.42+143.47%52W

Market Cap$2.67B

P/E—

PEG Ratio—

Div yield—

Beta1.78

NRIX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)39.91%

Price vs S&P 500 (4W)-2.57%

VGM Score83.50

Book Value / Share (Quarterly)$8.87

P/TBV (Annual)0.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)29.54%

Cash Flow / Share (Quarterly)$3.39

Price vs S&P 500 (YTD)16.80%

Net Profit Margin (TTM)42.01%

EPS (TTM)$2.31

10-Day Avg Trading Volume2.71M

EPS Excl Extra (TTM)$2.31

Revenue Growth (5Y)36.35%

EPS (Annual)$-3.05

ROI (Annual)-49.09%

Net Profit Margin (5Y Avg)-343.51%

Cash / Share (Quarterly)$9.60

P/E Basic Excl Extra (TTM)9.05x

Revenue Growth QoQ (YoY)8426.27%

ROA (Last FY)-38.43%

Revenue Growth TTM (YoY)738.76%

EBITD / Share (TTM)$2.76

ROE (5Y Avg)-50.25%

Operating Margin (TTM)41.27%

Cash Flow / Share (Annual)$-2.59

P/B Ratio2.76x

P/B Ratio (Quarterly)2.76x

Net Income / Employee (Annual)$-834,200

EV / Revenue (TTM)2.77x

ROA (TTM)38.61%

EV / EBITDA (TTM)6.53x

EPS Incl Extra (Annual)$-3.05

Current Ratio (Annual)7.02x

Quick Ratio (Quarterly)8.17x

3-Month Avg Trading Volume1.73M

52-Week Price Return143.47%

P/E Incl Extra (TTM)9.05x

Revenue / Employee (TTM)$2,214,300

Tangible BV / Share (Quarterly)$4.82

P/S Ratio (Annual)31.77x

Asset Turnover (Annual)0.12x

52-Week High$28.23

Operating Margin (5Y Avg)-360.87%

EPS Excl Extra (Annual)$-3.05

CapEx CAGR (5Y)25.21%

26-Week Price Return49.82%

Quick Ratio (Annual)6.86x

13-Week Price Return5.62%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)8.44x

Enterprise Value$1.95B

Revenue / Share Growth (5Y)16.14%

Asset Turnover (TTM)0.92x

Book Value / Share Growth (5Y)-6.64%

Revenue / Employee (Annual)$264,900

Pretax Margin (Annual)-314.00%

Cash / Share (Annual)$5.82

3-Month Return Std Dev36.22%

Net Income / Employee (TTM)$930,200

ROE (Last FY)-49.09%

EPS Basic Excl Extra (Annual)$-3.05

P/FCF (TTM)4.34x

Receivables Turnover (TTM)68.62x

EV / Free Cash Flow (TTM)5.27x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$2.31

Receivables Turnover (Annual)12.88x

ROI (TTM)49.34%

P/S Ratio (TTM)3.80x

Pretax Margin (5Y Avg)-343.14%

Revenue / Share (Annual)$0.97

Tangible BV / Share (Annual)$6.44

Forward P/E10.38x

Price vs S&P 500 (52W)127.94%

P/E Ratio (TTM)9.05x

Year-to-Date Return28.73%

5-Day Price Return10.20%

EPS Normalized (Annual)$-3.05

ROA (5Y Avg)-35.14%

Net Profit Margin (Annual)-314.90%

Month-to-Date Return2.99%

Cash Flow / Share (TTM)$-2.61

EBITD / Share (Annual)$-3.20

Operating Margin (Annual)-340.16%

P/CF (TTM)7.03x

ROI (5Y Avg)-50.25%

P/E Excl Extra (TTM)9.05x

EPS Basic Excl Extra (TTM)$2.31

P/TBV (Quarterly)1.29x

P/B Ratio (Annual)3.18x

Pretax Margin (TTM)43.91%

Book Value / Share (Annual)$5.29

Price vs S&P 500 (13W)2.94%

Beta1.78x

Revenue / Share (TTM)$6.04

ROE (TTM)49.34%

52-Week Low$9.71

vGradeB

gGradeA

mGradeA

vgmGradeA

NRIX Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q3 2026	Oct 12, 2026	$5.02	$4.73	-5.69%(-$0.29)
Q2 2026	Jul 9, 2026	-$0.72	-$0.81	-13.07%(-$0.09)
Q1 2026	Apr 8, 2026	-$0.76	-$0.79	-3.33%(-$0.03)
Q4 2025	Jan 28, 2026	-$0.92	-$0.82	+10.85%(+$0.10)
Q3 2025	Oct 9, 2025	-$0.85	-$1.03	-21.07%(-$0.18)

NRIX Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.30

4.23

4.24

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
NRIXNurix Therapeutics, Inc. Common stock	B	A	A	3.8x	738.8%	—	—	$24.42
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Nurix Therapeutics, Inc. Common stock

Nurix Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies for cancer and inflammatory diseases using an AI-enhanced discovery platform. The company's pipeline includes candidates such as Bexobrutideg and Zelebrudomide that target specific disease-causing proteins in immune and oncology-related pathways.

NRIX Insider Transactions

SellSep 2, 2026
RING CHRISTINE
Officer
Shares: 5,787Value: $149,072
SellSep 1, 2026
HANSEN GWENN M
Officer
Shares: 1,452Value: $36,982
SellAug 5, 2026
HANSEN GWENN M
Officer
Shares: 4,356Value: $108,900
SellAug 4, 2026
VAN HOUTE JOHANNES D
Chief Financial Officer
Shares: 4,761Value: $115,989
SellAug 4, 2026
HANSEN GWENN M
Officer
Shares: 4,111Value: $100,142

Open-market buys and sells filed with the SEC over the last 90 days. Grants, gifts and option exercises are excluded.

All insider transactions for September 2026

Companies in Related Industries

COTYCOTY INCCosmetics & Toiletries
DNLIDenali Therapeutics Inc. Common StockBiological Products
FULH.B. Fuller CompanyAdhesives & Sealants
WDFCWd-40 CoIndustrial Chemicals
NEOGNeogen CorpIn Vitro Diagnostics
BEAMBeam Therapeutics Inc. Common StockBiological Products
NGVTIngevity CorporationChemicals
ADMAADMA Biologics, Inc.Biological Products

Same SIC sector, outside this company's own industry.

Analyst Sentiment

4.2

Strong Buy

Consensus rating

52-Week Range

Low$9.71

High$28.23